Cargando…
MicroRNAs as therapeutic targets in cardiovascular disease
The discovery of microRNAs and their role in diseases was a breakthrough that inspired research into microRNAs as drug targets. Cardiovascular diseases are an area in which limitations of conventional pharmacotherapy are highly apparent and where microRNA-based drugs have appreciably progressed into...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9151703/ https://www.ncbi.nlm.nih.gov/pubmed/35642640 http://dx.doi.org/10.1172/JCI159179 |
_version_ | 1784717527868243968 |
---|---|
author | Laggerbauer, Bernhard Engelhardt, Stefan |
author_facet | Laggerbauer, Bernhard Engelhardt, Stefan |
author_sort | Laggerbauer, Bernhard |
collection | PubMed |
description | The discovery of microRNAs and their role in diseases was a breakthrough that inspired research into microRNAs as drug targets. Cardiovascular diseases are an area in which limitations of conventional pharmacotherapy are highly apparent and where microRNA-based drugs have appreciably progressed into preclinical and clinical testing. In this Review, we summarize the current state of microRNAs as therapeutic targets in the cardiovascular system. We report recent advances in the identification and characterization of microRNAs, their manipulation and clinical translation, and discuss challenges and perspectives toward clinical application. |
format | Online Article Text |
id | pubmed-9151703 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society for Clinical Investigation |
record_format | MEDLINE/PubMed |
spelling | pubmed-91517032022-06-02 MicroRNAs as therapeutic targets in cardiovascular disease Laggerbauer, Bernhard Engelhardt, Stefan J Clin Invest Review The discovery of microRNAs and their role in diseases was a breakthrough that inspired research into microRNAs as drug targets. Cardiovascular diseases are an area in which limitations of conventional pharmacotherapy are highly apparent and where microRNA-based drugs have appreciably progressed into preclinical and clinical testing. In this Review, we summarize the current state of microRNAs as therapeutic targets in the cardiovascular system. We report recent advances in the identification and characterization of microRNAs, their manipulation and clinical translation, and discuss challenges and perspectives toward clinical application. American Society for Clinical Investigation 2022-06-01 2022-06-01 /pmc/articles/PMC9151703/ /pubmed/35642640 http://dx.doi.org/10.1172/JCI159179 Text en © 2022 Laggerbauer et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Laggerbauer, Bernhard Engelhardt, Stefan MicroRNAs as therapeutic targets in cardiovascular disease |
title | MicroRNAs as therapeutic targets in cardiovascular disease |
title_full | MicroRNAs as therapeutic targets in cardiovascular disease |
title_fullStr | MicroRNAs as therapeutic targets in cardiovascular disease |
title_full_unstemmed | MicroRNAs as therapeutic targets in cardiovascular disease |
title_short | MicroRNAs as therapeutic targets in cardiovascular disease |
title_sort | micrornas as therapeutic targets in cardiovascular disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9151703/ https://www.ncbi.nlm.nih.gov/pubmed/35642640 http://dx.doi.org/10.1172/JCI159179 |
work_keys_str_mv | AT laggerbauerbernhard micrornasastherapeutictargetsincardiovasculardisease AT engelhardtstefan micrornasastherapeutictargetsincardiovasculardisease |